China Health Authority NMPA approved Cosentyx ® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first ...
The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
Sanofi is paying C4X Discovery €7 million upfront and committing to up to €407 million in milestones. (Sanofi) () Sanofi has licensed an oral IL-17A inhibitor from C4X Discovery. The deal positions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results